Start here if you're new
what it is
Century Therapeutics builds off-the-shelf immune cell treatments for cancer and autoimmune disease using stem cells from healthy donors.
how it gets paid
Last year Century Therapeutics made $109M in revenue.
why it's growing
Revenue grew 1556.8% last year. The weird part is the split screen. Quarterly EPS stayed negative at -$0.41 in Q4 2024.
what just happened
Quarterly history shows a $0.41 per-share loss in the latest quarter, while filings still showed $109 million in trailing revenue.
At a glance
C balance sheet — red flag territory — real financial stress
-$1.61 fy2024 eps est
$7M fy2024 rev est
15.8% operating margin
~$421M market cap
xvary composite: 19/100 — weak
What they do
Century Therapeutics builds off-the-shelf immune cell treatments for cancer and autoimmune disease using stem cells from healthy donors.
Its pitch is speed and scale. Allogeneic (donor-derived, not made from your own cells, so treatment can be produced in batches) is cheaper and faster if it works. CNTY-101 already carries 6 gene edits in Phase 1, which tells you this is really a platform bet, not a one-drug story.
How they make money
$109M
annual revenue · their business grew +1556.8% last year
total revenue
$109M
+1556.8%
The products that matter
allogeneic cell therapy platform
iPSC Platform
$109.2M collaboration revenue
this platform produced the $109.2M revenue spike, but it still has not produced an approved drug. you are buying research translated into milestones, not a finished product business.
platform
early clinical autoimmune program
CNTY-101
$7M FY2024 rev est backdrop
CNTY-101 is the lead asset readers actually need to care about because there is no product revenue to diversify the bet. if the lead program stumbles, the rest of the valuation has nowhere to hide.
lead program
Key numbers
$421M
market cap
You are paying $421 million today for a business with a 2024 sales estimate of just $7 million. That is the whole debate.
$7M
2024 sales est.
That sales estimate is tiny next to the valuation, which tells you the stock is priced on future trial success, not current business output.
$109M
TTM revenue
Filings show $109 million in trailing revenue, which clashes with the $7 million annual estimate and tells you revenue quality matters more than revenue size.
$1.61
2024 EPS est.
Losses are shrinking from -$1.94 to -$1.61, but you still own a company expected to lose money while its main asset stays in Phase 1.
Financial health
C
strength
- balance sheet grade C — very weak — significant financial distress
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $41M (9% of capital)
C — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for IPSC right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Quarterly history shows a $0.41 per-share loss in the latest quarter, while filings still showed $109 million in trailing revenue.
The weird part is the split screen. Quarterly EPS stayed negative at -$0.41 in Q4 2024, but annual and trailing revenue data show $109 million, pointing to collaboration-heavy revenue rather than a steady product business.
$109M
revenue
$0.41
eps
15.8%
operating margin
the number that mattered
The number that matters is $7 million versus $109 million. That gap tells you investors need to decide which revenue figure better reflects the real business.
source: company filings and quarterly history, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is collaboration revenue disappearing before the pipeline creates real value.
med
one partner drives the revenue story
The reported $109.2M revenue came from collaboration activity. If milestone timing changes or the partnership weakens, the business can swing back toward the $7M revenue level analysts currently expect.
That exposes nearly all reported revenue to a funding source that does not behave like product sales.
med
clinical failure would hit the whole thesis at once
There are no approved drugs here. The valuation rests on early programs like CNTY-101 proving the platform works in humans, not just on slides.
With a ~$421M market cap and no diversified product base, a bad data point can take a disproportionate amount of equity value with it.
med
cash burn can outrun the balance sheet
The company has a C balance sheet, $41M in long-term debt, and $61.9M in current assets. Early-stage biotech trials are expensive, and this snapshot does not show a self-funding commercial engine behind them.
More capital raising would likely mean dilution, tougher terms, or both.
If collaboration dollars fade before the clinic delivers, you are left with a volatile small-cap biotech and very little revenue support underneath it.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next earnings report
Estimated for May 11, 2026. You want two things: updated cash runway commentary and any change in collaboration revenue cadence.
trend
the drop from $109.2M to $7M
That forecast gap is the key insight on the page. If management cannot replace collaboration revenue with new milestones or stronger pipeline momentum, the headline profit will age badly.
risk
clinical updates on CNTY-101
This is the kind of catalyst that can move a small-cap biotech in one session. You are not looking for polish. You are looking for evidence the lead program is de-risking.
metric
balance sheet pressure
C balance sheet grade, $41M debt, and $61.9M current assets do not leave much room for clinical delays. Funding risk is not background noise here. It is part of the thesis.
Analyst rankings
risk profile
high risk
risk rank 5 — significant risk of large drawdowns.
chart momentum
below average
momentum rank 4 — analysts see underperformance risk in the near term.
source: institutional data
Institutional activity
institutional ownership data for IPSC is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive